PCRX - Pacira BioSciences, Inc.

22.86
0   0%

Share volume: 931,883
Last Updated: 03-05-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.31%

PREVIOUS CLOSE
CHG
CHG%
$22.86
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
36%
Profitability 26%
Dept financing 14%
Liquidity 70%
Performance 43%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
7.42%
1 Month
8.86%
3 Months
-6.39%
6 Months
-14.51%
1 Year
-4.19%
2 Year
-24.08%
Key data
Stock price
$22.86
P/E Ratio 
158.29
DAY RANGE
$22.42 - $23.28
EPS 
$0.16
52 WEEK RANGE
$18.80 - $27.64
52 WEEK CHANGE
-$2.18
MARKET CAP 
1.113 B
YIELD 
N/A
SHARES OUTSTANDING 
40.490 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-06-2025
BETA 
1.64
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,272,288
AVERAGE 30 VOLUME 
$887,130
Company detail
CEO: David M. Stack
Region: US
Website: pacira.com
Employees: 720
IPO year: 2011
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectionable suspension. iovera system produces controlled doses of cold temperature only to targeted nerves.

Recent news